Lalonde RG - Search Results

1

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.

Klein MB, Campeol N, Lalonde RG, Brenner B, Wainberg MA. Klein MB, et al. Among authors: lalonde rg. AIDS. 2003 May 2;17(7):1001-8. doi: 10.1097/01.aids.0000060357.78202.25. AIDS. 2003. PMID: 12700449

2

The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.

Klein MB, Lalonde RG, Suissa S. Klein MB, et al. Among authors: lalonde rg. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):365-72. doi: 10.1097/00126334-200307010-00011. J Acquir Immune Defic Syndr. 2003. PMID: 12843748

3

The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection.

Klein MB, Willemot P, Murphy T, Lalonde RG. Klein MB, et al. Among authors: lalonde rg. AIDS. 2004 Sep 24;18(14):1895-904. doi: 10.1097/00002030-200409240-00005. AIDS. 2004. PMID: 15353975

4

Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare.

Keller M, Lu Y, Lalonde RG, Klein MB. Keller M, et al. Among authors: lalonde rg. AIDS. 2009 Mar 27;23(6):731-7. doi: 10.1097/QAD.0b013e328326f77f. AIDS. 2009. PMID: 19279446

5

Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.

Mercure L, Lalonde R, Phaneuf D, Brenner B, Wainberg MA. Mercure L, et al. Clin Diagn Lab Immunol. 1994 Jul;1(4):482-5. doi: 10.1128/cdli.1.4.482-485.1994. Clin Diagn Lab Immunol. 1994. PMID: 8556489 Free PMC article.

6

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. Brenner BG, et al. J Virol. 2002 Feb;76(4):1753-61. doi: 10.1128/jvi.76.4.1753-1761.2002. J Virol. 2002. PMID: 11799170 Free PMC article.

7

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA. Beck EJ, et al. AIDS. 2004 Dec 3;18(18):2411-8. AIDS. 2004. PMID: 15622317

8

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.

Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB. Boulassel MR, et al. Among authors: lalonde rg. J Med Virol. 2006 Sep;78(9):1158-63. doi: 10.1002/jmv.20676. J Med Virol. 2006. PMID: 16847953 Clinical Trial.

9

Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, Micheli V, Brenner BG. Ntemgwa M, et al. Antimicrob Agents Chemother. 2007 Nov;51(11):3861-9. doi: 10.1128/AAC.00646-07. Epub 2007 Aug 27. Antimicrob Agents Chemother. 2007. PMID: 17724152 Free PMC article.

10

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.

Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP. Klein MB, et al. Can J Infect Dis Med Microbiol. 2011 Fall;22(3):88-96. doi: 10.1155/2011/686918. Can J Infect Dis Med Microbiol. 2011. PMID: 22942885 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters